Eterna Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| ETERNA THERAPEUTICS Inc. | ||
| Date: March 12, 2025 | By: | /s/ Sanjeev Luther |
|---|---|---|
| Sanjeev Luther | ||
| President, Chief Executive Officer, and Director (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Sanjeev Luther | President, Chief Executive Officer, and Director (Principal Executive Officer) | March 12, 2025 |
| Sanjeev Luther | ||
| /s/ Sandra Gurrola | Senior Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) | March 12, 2025 |
| Sandra Gurrola | ||
| /s/ James Bristol | Chairman of the Board | March 12, 2025 |
| James Bristol | ||
| /s/ Peter Cicala | Director | March 12, 2025 |
| Peter Cicala | ||
| /s/ Elena Ratner | Director | March 12, 2025 |
| Elena Ratner | ||
| /s/ William Wexler | Director | March 12, 2025 |
| William Wexler | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.